Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor
- PMID: 377491
- DOI: 10.1126/science.377491
Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor
Abstract
Subcutaneous injection of 50 micrograms of a long-acting analog of luteinizing hormone-releasing factor on each of two successive days during mid-luteal phase in normally cycling women induced a short luteal phase and premature menstruation. These events were associated with luteolysis, as evidenced by the consistent and parallel premature decline of progesterone and estradiol levels compared with those in control cycles. This finding may prove to be useful in the prevention or interception of implantation.
Similar articles
-
Accelerated dissolution of luteal-endometrial integrity by the administration of antagonists of gonadotropin-releasing hormone and progesterone to late-luteal phase women.Fertil Steril. 1990 Nov;54(5):805-10. Fertil Steril. 1990. PMID: 2226914 Clinical Trial.
-
Effect of postovulatory treatment with a luteinizing hormone-releasing hormone analog on the plasma level of progesterone in women.Fertil Steril. 1978 Nov;30(5):549-52. doi: 10.1016/s0015-0282(16)43636-8. Fertil Steril. 1978. PMID: 363461
-
Early follicular phase luteinizing hormone-releasing hormone agonist administration - effects on follicular maturation and corpus luteum function in women.Contraception. 1982 Jan;25(1):31-9. doi: 10.1016/0010-7824(82)90016-6. Contraception. 1982. PMID: 6800690
-
Gonadotropin-releasing hormone antagonists: effects on the ovarian follicle and corpus luteum.Clin Obstet Gynecol. 1993 Sep;36(3):744-52. doi: 10.1097/00003081-199309000-00031. Clin Obstet Gynecol. 1993. PMID: 8403621 Review. No abstract available.
-
Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function.Curr Opin Obstet Gynecol. 2007 Jun;19(3):258-65. doi: 10.1097/GCO.0b013e3281338874. Curr Opin Obstet Gynecol. 2007. PMID: 17495643 Review.
Cited by
-
Low Luteal Serum Progesterone Levels Are Associated With Lower Ongoing Pregnancy and Live Birth Rates in ART: Systematic Review and Meta-Analyses.Front Endocrinol (Lausanne). 2022 Jun 10;13:892753. doi: 10.3389/fendo.2022.892753. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35757393 Free PMC article.
-
Breast cancer prevention through modulation of endogenous hormones.Breast Cancer Res Treat. 1993 Nov;28(2):179-93. doi: 10.1007/BF00666430. Breast Cancer Res Treat. 1993. PMID: 8173070 Review.
-
LRFD6a has a dose-related stimulatory or inhibitory effect on the ovary in normal luteal phase women.J Endocrinol Invest. 1985 Aug;8(4):297-302. doi: 10.1007/BF03348501. J Endocrinol Invest. 1985. PMID: 3934254
-
Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.Endocr Rev. 2018 Oct 1;39(5):593-628. doi: 10.1210/er.2017-00236. Endocr Rev. 2018. PMID: 29982525 Free PMC article. Review.
-
The use of long-acting gonadotropin-releasing hormone agonist (GnRH-a; decapeptyl) and gonadotropins versus short-acting GnRH-a (buserelin) and gonadotropins before and during ovarian stimulation for in vitro fertilization (IVF).J In Vitro Fert Embryo Transf. 1991 Oct;8(5):254-9. doi: 10.1007/BF01139780. J In Vitro Fert Embryo Transf. 1991. PMID: 1836810 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources